7.58
Schlusskurs vom Vortag:
$7.52
Offen:
$7.56
24-Stunden-Volumen:
1.65M
Relative Volume:
0.69
Marktkapitalisierung:
$553.27M
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-1.6231
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
+2.43%
1M Leistung:
+1.88%
6M Leistung:
-58.40%
1J Leistung:
-73.86%
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Vergleichen Sie ARVN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ARVN
Arvinas Inc
|
7.58 | 540.14M | 161.10M | -308.60M | -259.90M | -4.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2025-05-05 | Herabstufung | Truist | Buy → Hold |
2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
2024-12-10 | Eingeleitet | BTIG Research | Buy |
2024-11-18 | Eingeleitet | Stephens | Overweight |
2024-02-28 | Bestätigt | Oppenheimer | Outperform |
2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
2024-02-01 | Eingeleitet | Goldman | Buy |
2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2022-09-09 | Eingeleitet | Barclays | Overweight |
2022-06-21 | Eingeleitet | Jefferies | Hold |
2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
2022-01-19 | Eingeleitet | Goldman | Buy |
2021-12-07 | Eingeleitet | Cowen | Outperform |
2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
2021-09-30 | Eingeleitet | Stifel | Buy |
2021-09-09 | Eingeleitet | BofA Securities | Buy |
2021-05-21 | Eingeleitet | UBS | Buy |
2021-04-21 | Eingeleitet | Truist | Buy |
2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
2020-05-12 | Eingeleitet | Oppenheimer | Perform |
2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
2019-11-25 | Eingeleitet | Guggenheim | Buy |
2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
2019-09-25 | Eingeleitet | Wedbush | Outperform |
2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
2018-10-22 | Eingeleitet | Citigroup | Buy |
2018-10-22 | Eingeleitet | Goldman | Neutral |
2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
What drives Arvinas Inc. stock priceExplosive returns - jammulinksnews.com
What analysts say about Arvinas Inc. stockFastest-growing stock picks - jammulinksnews.com
Arvinas (ARVN) to Release Earnings on Tuesday - MarketBeat
Is Arvinas Inc. a good long term investmentSignificant capital appreciation - PrintWeekIndia
Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment - MSN
Arvinas Inc. Stock Analysis and ForecastFree Stock Selection - PrintWeekIndia
Arvinas, Inc. (NASDAQ:ARVN) Receives $20.29 Consensus Price Target from Analysts - MarketBeat
13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey
(ARVN) Proactive Strategies - news.stocktradersdaily.com
Arvinas (NASDAQ:ARVN) Trading Down 4.6%Here's Why - MarketBeat
Arvinas: A Potential 'Sum Of The Parts' Story (NASDAQ:ARVN) - Seeking Alpha
Arvinas CEO John Houston to retire - MSN
Arvinas stock slides after eliminating trials, reducing workforce - MSN
Arvinas CEO John Houston to retire, remain as board chair By Investing.com - Investing.com South Africa
Becton Dickinson, Spotify, Arvinas, Twilio, Lumen: Trending by Analysts - MSN
Arvinas (ARVN) Soars 2.62% on CEO Transition - AInvest
Arvinas CEO John Houston to retire, remain as board chair - Investing.com Australia
Gilead signs lenacapavir access deal; Arvinas CEO to step down - BioPharma Dive
Arvinas Announces Retirement of CEO John Houston, Ph.D., - citybiz
Arvinas CEO John Houston to retire after successor is named, will remain board chair - Investing.com Nigeria
Arvinas CEO John Houston to retire after successor is named, will remain board chair By Investing.com - Investing.com South Africa
Arvinas' CEO to Retire; Search for Successor Begins - MarketScreener
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan - The Manila Times
Pioneering Biotech CEO Steps Down: How Arvinas' Houston Transformed Protein Degradation Drug Development - Stock Titan
Arvinas announces board resignation and reports annual meeting voting results By Investing.com - Investing.com South Africa
Arvinas, Inc. Announces John Young Decides to Resign from its Board of Directors and Compensation Committee, Effective June 30, 2025 - MarketScreener
Arvinas announces board resignation and reports annual meeting voting results - Investing.com
Arvinas, Inc. (NASDAQ:ARVN) CFO Andrew Saik Sells 5,700 Shares - MarketBeat
Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm - TradingView
Arvinas (NASDAQ:ARVN) Shares Gap UpStill a Buy? - MarketBeat
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Logos Global Management LP Acquires 4,800,000 Shares in Arvinas Inc - GuruFocus
Logos Global Management LP Issues a Letter to the Board of Arvinas, Inc. - MarketScreener
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade - MSN
Arvinas’s SWOT analysis: vepdegestrant efficacy fuels stock potential amid market challenges - Investing.com
Analysts Set Expectations for Arvinas FY2026 Earnings - MarketBeat
ARVN: Arvinas' ARV-393 Shows Promise in Preclinical Lymphoma Stu - GuruFocus
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma - marketscreener.com
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV- - GuruFocus
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):